Related by context. All words. (Click for frequent words.) 70 relapsed MM 70 galiximab 70 Pivotal Phase III 69 including eniluracil ADH 69 Cloretazine ® 69 Annamycin 69 CINQUIL 69 BRIM2 69 Evoltra ® 69 novel VDA molecule 69 Phase 2b Clinical Trial 68 metaglidasen 68 IMA# 68 Troxatyl 68 OvaRex ® MAb 68 PNP inhibitor 68 Phase #/#a trial 68 Meets Primary Endpoint 68 dasatinib Sprycel ® 68 Vicriviroc 68 phase IIb clinical 68 ruxolitinib 68 BRIM3 68 myelodysplastic myeloproliferative diseases 68 oral prodrug 68 rALLy trial 68 CYT# potent vascular disrupting 68 orally administered inhibitor 67 phase IIb study 67 ChronVac C R 67 Xanafide 67 riociguat 67 Dacogen injection 67 forodesine 67 Hedgehog Pathway Inhibitor 67 elacytarabine 67 TBC# 67 Forodesine HCl 67 MKC# MT 67 Phase IIIb clinical 67 ZOLINZA 67 Ceflatonin 67 Ophena TM 67 heavily pretreated 67 assessing T DM1 67 Cloretazine R 67 oral picoplatin 67 LHRH receptor positive 67 refractory chronic lymphocytic 67 budesonide foam 67 rALLy clinical trial 67 Aflibercept 67 Elagolix 67 forodesine hydrochloride 67 severe hypercholesterolemia 67 lintuzumab SGN 67 alvespimycin 66 Plicera 66 unique alkylating agent 66 receptor tyrosine kinase inhibitor 66 generation purine nucleoside 66 lumiliximab 66 systemic ALCL 66 Targretin capsules 66 Bezielle 66 refractory metastatic colorectal cancer 66 Mipomersen 66 LymphoStat B belimumab 66 eosinophilic asthma 66 Panzem R NCD 66 relapsed refractory multiple myeloma 66 relapsed leukemia 66 catheter occlusion 66 oral nucleoside analogue 66 dose escalation phase 66 acetonide FA 66 Cloretazine 66 ELACYT 66 #I TM# 66 ALN VSP Phase 66 UPLYSO 66 Zemplar Capsules 66 Archexin 66 Brentuximab Vedotin SGN 66 GOUT 66 OvaRex R 66 SinuNase TM 66 metastatic renal cell 66 HDAC Inhibitor 66 R lenalidomide 66 phase IIa clinical 66 Initiate Phase 66 oral ridaforolimus 66 CHAMPION PCI 66 Alocrest 66 Matrix Phase 2b 66 hypereosinophilic syndrome 66 leukemia AML 66 systemic anaplastic large 66 TASKi2 66 MAGE A3 ASCI 66 VEGFR2 inhibitor 66 Azedra 66 TELINTRA 66 Golimumab 66 GALNS 66 non metastatic osteosarcoma 66 successfully commercialize Iluvien 66 recurrent glioblastoma multiforme 66 PSN# [002] 66 CALGB # [002] 66 cutaneous T 66 cystinosis patients 66 Cloretazine R VNP#M 66 relapsed ALL 66 CCX# 66 MKC# 66 Phase #b/#a clinical 65 Pivotal Phase 65 canakinumab 65 Telintra 65 SPRYCEL ® 65 CCR9 antagonist 65 ospemifene 65 OMP #R# 65 Prostate AdenoCarcinoma Treatment 65 YONDELIS 65 Pimavanserin 65 DEB# 65 ORENCIA ® 65 Bayer HealthCare Onyx Pharmaceuticals 65 Exelixis compounds 65 Phase IIa trials 65 Combination REOLYSIN R 65 PANVAC VF 65 PNH patients 65 lenalidomide Revlimid R 65 Randomized Phase 65 dosing cohort 65 acyclovir Lauriad R 65 vidofludimus 65 Aryplase 65 Phase III randomized controlled 65 EOquin TM 65 crizotinib PF # 65 chronic eosinophilic leukemia 65 leading oral taxane 65 refractory metastatic 65 indolent follicular non 65 herpetic keratitis 65 induced macular edema 65 omacetaxine mepesuccinate 65 novel histone deacetylase 65 hoFH 65 Fibrillex TM 65 IL# PE#QQR 65 phase III isavuconazole 65 INCB# [001] 65 MDS AML 65 opioid naive 65 Sapacitabine 65 biliary tract cancer 65 HGS ETR2 65 Romidepsin 65 esophageal candidiasis 65 R#/MEM # 65 lymphoid malignancies 65 ALN PCS 65 Demonstrates Positive 65 fosbretabulin 65 Diabetic Macular Edema 65 dirucotide MBP# 65 CIMZIA TM certolizumab pegol 65 Initiates Phase III 65 Newly Diagnosed Multiple Myeloma 65 Phase IIb Clinical Trial 65 Phenoptin 65 BR.# 65 recurrent malignant glioma 65 dexanabinol 65 HeFH 65 mGluR5 NAM 65 Alzhemed TM 65 retinal vein occlusion induced 65 gefitinib Iressa 65 evaluating mipomersen 65 IMPACT DCM 65 omega interferon 65 Raptiva ® 65 Achieves Primary Endpoint 65 BrachySil TM 65 refractory gout 65 mRCC 65 Initiates Enrollment 65 Pafuramidine 65 DCCR 65 Phase Ib II 65 lomitapide 65 Phase III Pivotal 65 APEX PD 64 CIMZIA ™ 64 candidate CRLX# 64 reslizumab 64 XL# SAR# 64 haematologic 64 naïve HCV 64 CLARITY study 64 phase IIIb 64 metastatic malignant 64 Initiate Clinical Trial 64 Tesmilifene 64 AGILECT R 64 anti angiogenic agents 64 Vidaza R 64 Aplidin 64 Recurrent Glioblastoma 64 Zenvia ™ 64 Onalta ™ 64 Azedra TM 64 invasive candidiasis 64 Phase 1a clinical 64 elotuzumab 64 pediatric acute lymphoblastic 64 PRIMO CABG 64 antibody MAb 64 Marqibo 64 Phase Ib study 64 Vitaxin 64 nilotinib 64 octreotide implant 64 Virulizin ® 64 dextofisopam 64 polycythemia vera essential thrombocythemia 64 Cutaneous T 64 GATTEX ™ 64 DXL# 64 recurrent glioma 64 CRLX# 64 KRN# 64 tramiprosate Alzhemed TM 64 dose escalation Phase 64 mCRC patients 64 MPS IVA 64 Pemetrexed 64 registrational trial 64 targeted radiotherapeutic 64 PI3K/Akt pathway inhibitor 64 IRX 2 64 azilsartan medoxomil 64 opioid induced bowel dysfunction 64 metastatic hormone refractory 64 Daclizumab 64 fallopian tube cancers 64 Hormone Refractory Prostate Cancer 64 investigational monoclonal antibody 64 erlotinib Tarceva ® 64 HER2 positive metastatic breast 64 Peginterferon alfa 2b 64 Stedivaze 64 Hodgkin lymphoma HL 64 Phase Ib clinical 64 demonstrated antitumor activity 64 refractory NSCLC 64 relapsing remitting MS RRMS 64 Patients Treated With 64 Personalized Immunotherapy 64 Anturol TM 64 ANCHOR trial 64 Phase III Clinical Trial 64 acute GvHD 64 Prodarsan R 64 dasatinib Sprycel 64 metastatic colorectal 64 Completes Patient Enrollment 64 Phase IIb Trial 64 Pharmacokinetics PK 64 MKC# MKC# PP 64 cognitive impairment associated 64 Campath alemtuzumab 64 Zenvia TM 64 treatment naive genotype 64 oxymorphone ER 64 recurrent herpes labialis 64 PERSEUS 64 neratinib 64 Temsirolimus 64 GVAX ® 64 GetGoal Phase III 64 Phase 2a trial 64 huC# DM4 64 Dyloject TM 64 metastatic CRC 64 sunitinib malate 64 ONCONASE R 64 E1 INT TM 64 kidney urologic 64 MEK Inhibitor 64 p# biomarker 64 HQK 64 oral rivaroxaban 64 SUPPRELIN R LA 64 Lenocta TM 64 Traficet EN 64 pediatric malignancies 64 Amrubicin 64 Icatibant 64 Investigational Treatment 64 Lupus Nephritis 64 sapacitabine CYC# 64 RANK Ligand inhibitor 64 trastuzumab DM1 T DM1 64 HCD# [002] 64 myelofibrosis polycythemia vera 64 aflibercept VEGF Trap 64 refractory CLL 64 Phase IIIb 64 Omacetaxine 64 HBeAg + 64 Investigational Oral 64 regorafenib 64 LymphoStat B TM 64 hemodynamically significant 64 EDEMA3 trial 64 relapsed AML 64 Pegylated Interferon 64 initiated Phase Ib 64 thalidomide Thalomid 64 allogeneic HSCT 64 refractory acute myeloid 64 OMNARIS HFA 63 docetaxel Taxotere ® 63 TMC# [002] 63 Pazopanib 63 Chronic Myeloid Leukemia 63 MEND CABG II 63 Severe Sepsis 63 COMFORT II 63 enzastaurin 63 THALOMID 63 XL# anticancer compounds 63 Xelox 63 TASKi3 63 Vidaza ® 63 constipation OIC 63 paclitaxel Taxol R 63 alefacept 63 Soft Tissue Sarcoma 63 advanced carcinoid 63 baminercept 63 alemtuzumab Campath 63 Bosutinib 63 cell lymphoma CTCL 63 nilotinib Tasigna ® 63 tezampanel NGX# 63 metastatic castrate resistant 63 Initiates Phase II 63 Cerebril TM 63 VNP#M 63 JAK#/JAK# inhibitor CYT# 63 PrevOnco 63 Velcade bortezomib 63 Solazed TM 63 NOX E# 63 tumors GIST 63 Tanespimycin 63 ATL# [001] 63 Enzastaurin 63 PEGINTRON TM 63 PDE# inhibitors 63 Kamada AAT 63 relapsed MCL 63 ularitide 63 unresectable recurrent 63 intranasal formulation 63 Patient Enrollment 63 Sutent sunitinib 63 neurologic progression 63 cetuximab Erbitux R 63 rindopepimut 63 oncolytic virus therapies 63 Triapine 63 Epratuzumab 63 Specifid 63 EOquin 63 severe gastroparesis 63 SNT MC# 63 Val HeFT 63 cancer neuroendocrine tumor 63 urocortin 2 63 OHR/AVR# 63 recurrent GBM 63 Letairis ambrisentan 63 completely resected 63 MabThera Rituxan 63 Androxal TM 63 CR# vcMMAE 63 miconazole Lauriad 63 Pivotal Trial 63 certolizumab 63 TransVax ™ 63 imatinib Gleevec ® 63 MEND CABG 63 pertuzumab 63 refractory colorectal cancer 63 Onrigin 63 ALN HPN 63 Myelofibrosis 63 LEUKINE 63 torezolid phosphate 63 Acute Myeloid Leukaemia AML 63 R roscovitine 63 PROSTVAC VF 63 AVOREN 63 refractory indolent non 63 evaluating Prochymal 63 Hsp# Inhibitor 63 beta 1a 63 compound INCB# 63 ThermoDox ® clinical 63 recurrent metastatic ovarian cancer 63 Twinrix 63 Proellex TM 63 unresectable stage 63 Gastrointestinal Stromal Tumors 63 pharmacokinetic PK study 63 mitoxantrone plus 63 Metastatic Melanoma 63 TLK# 63 HGS# 63 adalimumab Humira 63 www.soliris.net 63 Clolar ® 63 virus HCV protease inhibitor 63 maximally tolerated dose 63 chronic idiopathic thrombocytopenic purpura 63 generation URAT1 inhibitor 63 Completes Enrollment 63 R sorafenib tablets 63 Safinamide 63 relapsed mantle 63 delivers fluocinolone acetonide FA 63 AEG# 63 Quinamed 63 IMPDH inhibitor 63 Phase III ADT 63 TO AVOID PREGNANCY WHILE 63 Cimzia ® certolizumab pegol 63 Motesanib 63 PROVENGE sipuleucel T 63 metastatic castration resistant 63 CTAP# Capsules 63 DDP# 63 PRT# 63 GLP toxicology studies 63 resectable pancreatic cancer 63 HIV HCV coinfected 63 Degarelix 63 ATPace TM 63 Initiated Phase 63 haematological malignancies 63 Fludarabine 63 Phase #b/#a trial 63 CIMZIA TM 63 BRAF mutant 63 Factor VIIa 63 Presents Positive 63 unresectable tumors 63 Phase III Trial 63 Spiegelmer ® 63 PEG PAL 63 Demonstrates Significant 63 anthracyclines taxanes 63 XOMA 3AB 63 relapsed refractory AML 63 MCSP respectively 63 recurrent NSCLC 63 Fabry Disease 63 interferon alpha IFN 63 atypical hemolytic uremic syndrome 63 Kit CD# positive 63 evaluating tivozanib 63 tubulin inhibitor 63 DU #b 63 G#DT 63 TTF Therapy 63 Navelbine ® 63 oral talactoferrin 63 metastatic GIST 63 velafermin 63 AAG geldanamycin analog 63 ara C 63 BARACLUDE ® 63 ONTAK 63 2 inhibitor CYT# 63 KIACTA ™ 63 papillary renal cell carcinoma 63 PEG SN# 63 huN# DM1 63 vinorelbine tartrate 63 null responder 63 hyperphenylalaninemia HPA due 63 RAPTIVA 63 amrubicin 63 Fx #A 63 reduce serum phosphate 63 eculizumab therapy 63 eritoran 62 Altastaph 62 Evoltra 62 Ribavirin causes 62 evaluating Actimmune 62 IOP lowering 62 achieved CCyR 62 Amgen Neulasta R 62 immunotherapeutic agent 62 Talotrexin 62 pediatric pontine glioma 62 squalamine 62 sorafenib Nexavar 62 Zemiva TM 62 lymphoma CTCL 62 Randomized Phase II 62 antiangiogenic agents 62 Flu Cy 62 metastatic HRPC 62 TKB# 62 Zoraxel 62 albiglutide 62 previously untreated follicular 62 sarcoma melanoma 62 recombinant PSMA vaccine 62 Synta Announces 62 pharmacogenomic translational research 62 Phase IIb trials 62 REMINYL ® 62 myelofibrosis MF 62 Pegloticase 62 OncoVEX GM CSF 62 corticosteroid dexamethasone 62 TNF antagonist 62 multiple myeloma MM 62 IMPACT DCM trial 62 Soliris eculizumab 62 phase IIb trial 62 smoldering multiple myeloma 62 SUCCEED trial 62 XmAb ® 62 thrombin inhibiting aptamer 62 keloid scarring 62 Pivotal Study 62 ThermoDox R 62 evaluating Xcytrin 62 decompensated liver disease 62 CD# CEA 62 TTR amyloidosis 62 farletuzumab 62 TRIOLEX HE# APOPTONE HE# 62 MyVax R 62 Pivotal Clinical Trial 62 RhuDex R 62 AKT inhibitor 62 CA9 SCAN 62 multicenter Phase III 62 MERLIN TIMI 62 Anti VEGF 62 diabetic neuropathic pain 62 Tarceva TM 62 M# rationally 62 humanised monoclonal antibody 62 dopamine partial agonist 62 oral methylnaltrexone 62 Squalamine 62 cMET 62 Adjuvant Treatment 62 EVIZON TM squalamine lactate 62 SILENOR 62 orally inhaled migraine 62 ribavirin RBV 62 registrational Phase 62 IMC #B 62 Prospective Randomized 62 LibiGel ® 62 EDEMA3 62 Clinical Trial Results 62 gastrointestinal stromal tumors GIST 62 talactoferrin 62 XL# XL# 62 Renal Cell Carcinoma RCC 62 chronic myeloid 62 TRANSFORMS 62 IMPACT DCM clinical 62 HCV SPRINT 62 LibiGel testosterone gel 62 T1c 62 Decitabine 62 Saxagliptin 62 Multiple Ascending Dose 62 REVIVE Diabetes 62 telomerase therapeutic 62 humanized therapeutic 62 calcineurin inhibitor 62 diarrhea predominant irritable 62 tanespimycin 62 XL# XL# XL# 62 Phase #/#a 62 patientswith 62 Clofarabine 62 recurrent glioblastoma multiforme GBM 62 SUTENT ® 62 relapsed multiple myeloma 62 HoFH 62 RezularTM 62 Myelodysplastic Syndrome MDS 62 Phase Ib IIa 62 AP# [003] 62 FOLOTYN ® 62 Arranon 62 QNEXA ® 62 pediatric Crohn disease 62 maribavir 62 haematological cancers 62 Xcytrin R 62 Marqibo TM 62 INC# 62 ganetespib 62 PGL# 62 myeloproliferative diseases 62 HCV RESPOND 2 62 number NCT# ClinicalTrials.gov 62 ORENCIA R 62 evaluating T DM1 62 seliciclib CYC# 62 CANCIDAS 62 AZILECT R 62 Vidaza azacitidine 62 malignant ascites 62 Gleevec Glivec 62 follicular lymphoma FL 62 AeroLEF TM 62 tafamidis 62 Glufosfamide 62 pan histone deacetylase 62 p# inhibitor 62 EFAPROXYN 62 Gleevec resistant 62 essential thrombocythemia ET 62 placebo controlled Phase 62 VP# [004] 62 multicenter placebo controlled 62 Catena ® 62 cancer mCRC 62 TOCOSOL Camptothecin 62 zanolimumab 62 REG1 Anticoagulation System 62 TELCYTA 62 Zolinza 62 novel oral anticoagulant 62 trial evaluating PRX# 62 Phase III Clinical Trials 62 HuMax EGFr 62 ATACAND 62 autologous cellular immunotherapy 62 castrate resistant prostate cancer 62 non splenectomized 62 Vicinium TM 62 MELAS 62 EGS# 62 treat chronic sinusitis 62 AGHD 62 teriflunomide 62 mapatumumab 62 either acutely decompensated 62 biologic therapy 62 MGd 62 randomized controlled Phase 62 Panzem R 62 Fludara ® 62 deforolimus 62 systemic RNAi therapeutic 62 phase Ib 62 AA Amyloidosis 62 Phase 1b clinical trials 62 aldehyde dehydrogenase ALDH2 deficiency 62 verteporfin 62 Tasimelteon 62 dose escalation clinical 62 IAP inhibitor 62 Femara letrozole 62 Omapro 62 briakinumab 62 Phase IIa trial 62 Levetiracetam 62 TroVax ® 62 ® bortezomib 62 MIST II 62 CEQ# 62 bavituximab monotherapy trial 62 histone deacetylase HDAC inhibitor 62 EndoTAG TM -1 62 candidate TNFerade biologic 62 Initiates Clinical 62 Firazyr 62 Behcet uveitis 62 PREOS R 62 celgosivir 62 bosutinib 62 terlipressin 62 myocardial infarction ventricular fibrillation 62 bardoxolone methyl 62 pegylated interferon alpha 62 sublingual tablets 62 ZACTIMA 62 EVIZON TM 62 Zavesca r 62 CLL SLL 62 lintuzumab 62 epigenetic therapies 62 clinical trials Archexin 62 Tyrima 62 cetuximab Erbitux 62 chronic thromboembolic pulmonary 62 Acute Ischemic Stroke 62 Phase IIb III 62 sodium thiosulfate STS 62 K ras mutations 62 induce remission 62 intravenous RSD# 62 HDL Selective Delipidation 62 RhuDex TM 62 hematological malignancy 62 ENDEAVOR III 62 Solazed 62 blinded randomized placebo controlled 62 Octreolin 62 midstage clinical 62 fusion enhancers 62 PLK1 SNALP 62 via intradermal injections 62 BENLYSTA ® 62 AVN# Phase 62 MOZOBIL 62 Preclinical studies suggest 62 Iluvien TM 62 HGS ETR1 62 intravenous belinostat 62 Syncria 62 Oral Fingolimod 62 relapsed SCLC 62 subcutaneous formulation 62 miconazole Lauriad ® 62 BENLYSTA TM 62 Fast Track Status 62 Dacogen decitabine 62 selective androgen receptor modulator 62 incyclinide 62 overactive bladder syndrome 62 Medullary Thyroid Cancer 62 refractory CTCL 62 Crofelemer budesonide foam 62 ENMD # 62 Corlux 62 Microplasmin 62 investigational therapies 62 ® lenalidomide 62 Epanova 62 BRAF inhibitor 62 Successfully Completes Phase 62 Sprycel dasatinib 62 brivaracetam 62 trastuzumab DM1 62 anagrelide 62 Viprinex TM 62 Doxil ® 62 Ketotransdel 62 Major Depressive Disorder MDD 62 immunomodulatory therapy 62 ACZ# 61 sorafenib tablets 61 radezolid 61 generation PNP inhibitor 61 neovascular diseases 61 topically administered 61 Presents Preclinical 61 Proxinium TM 61 FOLFIRI alone 61 Neuvenge 61 ZEVALIN ® 61 Phase 2b kidney transplant 61 Begins Dosing 61 Peginterferon Alfa 2a 61 Benlysta belimumab 61 Fingolimod 61 Sipuleucel T 61 Hepatocellular Carcinoma HCC 61 sargramostim 61 herpes zoster shingles 61 dirucotide 61 Lenocta 61 lucinactant 61 icatibant 61 Thalomid ® 61 Phase III Psoriasis 61 painful diabetic neuropathy 61 antiretroviral naïve 61 PDE4 inhibitor 61 proteasome inhibitor 61 Allovectin 7 61 OvaRex 61 refractory cutaneous T 61 dacarbazine DTIC 61 Dasatinib 61 Initiates Phase 2b 61 oral FTY# 61 plasma kallikrein inhibitor 61 pain palliation 61 PROVENGE ® 61 Randomized Double blind 61 Carfilzomib 61 Tectin TM 61 evaluating picoplatin 61 oropharyngeal candidiasis OPC 61 myeloproliferative neoplasms MPNs 61 paclitaxel poliglumex 61 Soliris TM eculizumab 61 Bayer Nexavar 61 dextromethorphan quinidine 61 non nucleoside inhibitor 61 Overactive Bladder OAB 61 Capesaris 61 Sudhir Agrawal D.Phil 61 protein kinase inhibitor 61 personalized cellular immunotherapy 61 atypical Hemolytic Uremic Syndrome 61 metastatic CRPC 61 IRESSA 61 HIV coinfected 61 PROSTVAC TM 61 Phase 2b Trial 61 Onco TCS 61 OMNARIS Nasal Spray 61 Antitumor Activity 61 samalizumab 61 diagnosed Ph + 61 Parathyroid Hormone 61 immunotherapeutic vaccine 61 GAMMAGARD 61 prospectively defined 61 Testosterone MDTS ® 61 GEM OS2 61 noninfectious uveitis 61 Cimzia TM 61 MOVIPREP R 61 ChronVac C 61 Retisert TM 61 5 fluorouracil leucovorin 61 interferon gamma 1b 61 candidates Dyloject TM 61 BEXXAR Therapeutic Regimen 61 EGFR TKI 61 Aurexis 61 CCR5 mAb 61 midstage trials 61 randomized Phase IIb 61 EGFR mutation positive 61 acute mania 61 hypoxia activated prodrug 61 Maribavir 61 ISIS # 61 Phase Ia 61 dimebon latrepirdine 61 adult chronic ITP 61 rheumatoid arthritis psoriatic arthritis 61 Preclinical Models 61 Cloretazine VNP#M 61 liposomal amphotericin B 61 resistant hormone refractory 61 next generation URAT1 61 homozygous familial hypercholesterolemia 61 EVIZON ™ 61 RhuDex 61 Ragweed Allergy 61 ACTEMRA TM 61 Myocet 61 Diabetic Neuropathy 61 trastuzumab Herceptin ® 61 axitinib 61 Complicated Skin 61 Genasense ® oblimersen 61 TM pralatrexate injection 61 Phase 2b study 61 SEPET TM 61 Ceflatonin R 61 Inhalation Solution 61 GRN# 61 RhuDex ® 61 de novo AML 61 MediGene focuses 61 systemic juvenile idiopathic 61 acute leukemias 61 Advaxis Phase 61 metastatic malignant melanoma 61 PROMACTA 61 preclinical efficacy 61 FOLFOX6 chemotherapy regimen 61 recurrent metastatic 61 placebo controlled Phase III 61 follicular Non Hodgkin 61 INTEGRILIN R eptifibatide Injection 61 Trofex 61 FDA APPROVES 61 AQ4N 61 selective modulator 61 Vertex hepatitis C 61 KRAS mutations occur 61 leukemia ALL 61 Anthracycline 61 TYZEKA 61 humanized interleukin 6 61 oral proteasome inhibitor 61 NSABP C 61 metastatic gastric 61 BrachySil 61 TACI Ig 61 colesevelam HCl 61 nephropathic cystinosis cystinosis 61 efaproxiral 61 Fast Track designations 61 Entereg R 61 phase IIa 61 anticancer compound 61 denileukin diftitox 61 phase III ACCLAIM 61 bone marrow reticulin deposition 61 Central Retinal Vein 61 ALK inhibitors 61 imatinib therapy 61 labial herpes 61 TRAIL receptor antibodies 61 hormone LHRH antagonist 61 Darinaparsin 61 rufinamide 61 vemurafenib 61 Tumor Response 61 Philadelphia Chromosome Positive 61 Pralatrexate 61 nonsmall cell lung cancer 61 registrational 61 Xcellerated T Cells 61 Seliciclib 61 Laquinimod 61 multicenter randomized placebo controlled 61 Vascular Disrupting Agent 61 Actimmune ® 61 SNT-MC#/idebenone 61 thorough QT 61 ILLUMINATE 61 Telik logo TELINTRA 61 Oral Calcitonin 61 evaluating satraplatin 61 Known hypersensitivity 61 response pCR 61 VICTOR E3 61 Relapsed Multiple Myeloma 61 PXD# 61 gemcitabine Gemzar ® 61 zileuton CR 61 ceftazidime 61 Phase III HEAT 61 oral JAK1 61 Orphan Status 61 Vascugel ® 61 low dose cytarabine 61 AVASTIN 61 steroid refractory GvHD 61 SPIRIT FIRST 61 ONCASPAR 61 refractory AML 61 docetaxel Taxotere R 61 inhaled treprostinil 61 6R BH4 61 compound AEZS 61 Alemtuzumab 61 Panzem NCD 61 gastrointestinal stromal tumor GIST 61 metastatic pancreatic 61 NATRECOR ® 61 ritonavir boosted protease inhibitor 61 indiplon capsules 61 Non Alcoholic Steatohepatitis 61 subcutaneous immunoglobulin 61 RSR# 61 Study Evaluating 61 Intravenous immunoglobulin 61 Pyridorin 61 IMPACT IMmunotherapy 61 Atypical Hemolytic Uremic Syndrome 61 Omnitarg 61 NU# direct 61 relapsing multiple sclerosis